secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2026-04-27T23:59:59+00:00
Accession:  0001193125-26-179404
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics reports 44% ORR for zovegalisib triplet; plans Phase 3 in frontline breast cancer
--------------------------------------------------------------------------------

- ORR of 44% (15/34) in heavily pre-treated, CDK4/6-experienced patients; 85% tumor reduction.
- Grade 3 hyperglycemia 0% despite 47% pre-diabetic; only 3% discontinued zovegalisib due to TRAEs.
- Phase 3 trial of zovegalisib + atirmociclib + AI in 1L PIK3CA-mutated HR+/HER2- breast cancer expected to start early 2027.
- Pfizer to supply atirmociclib and palbociclib for the trial; Relay retains full rights to zovegalisib.
- Median follow-up 7.4 months; 77% of patients remain on study; median PFS not yet mature.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000119312526179404/0001193125-26-179404-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000119312526179404/rlay-20260427.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-179404

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer